View in EDS HTML Full Text PDF Full Text

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Saved in:
Bibliographic Details
Title: A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Authors: Collier KA; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Valencia H; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Newton H; Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Hade EM; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA., Sborov DW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Cavaliere R; Division Neuro-Oncology, Department of Cancer Medicine, Baptist MD Anderson, Jacksonville, FL, USA., Poi M; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Phelps MA; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Liva SG; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Coss CC; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Wang J; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Khountham S; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Monk P; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Shapiro CL; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA., Piekarz R; National Cancer Institute/Cancer Therapy Evaluation Program, Bethesda, MD, USA., Hofmeister CC; Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA., Welling DB; Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, Boston, MA, USA., Mortazavi A; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA. Amir.Mortazavi@osumc.edu.
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 May; Vol. 87 (5), pp. 599-611. Date of Electronic Publication: 2021 Jan 25.
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33492438
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Collier+KA%22">Collier KA</searchLink>; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Valencia+H%22">Valencia H</searchLink>; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Newton+H%22">Newton H</searchLink>; Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Hade+EM%22">Hade EM</searchLink>; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Sborov+DW%22">Sborov DW</searchLink>; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.<br /><searchLink fieldCode="AU" term="%22Cavaliere+R%22">Cavaliere R</searchLink>; Division Neuro-Oncology, Department of Cancer Medicine, Baptist MD Anderson, Jacksonville, FL, USA.<br /><searchLink fieldCode="AU" term="%22Poi+M%22">Poi M</searchLink>; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Phelps+MA%22">Phelps MA</searchLink>; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Liva+SG%22">Liva SG</searchLink>; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Coss+CC%22">Coss CC</searchLink>; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; College of Pharmacy, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Khountham+S%22">Khountham S</searchLink>; Division of Hematology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Monk+P%22">Monk P</searchLink>; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Shapiro+CL%22">Shapiro CL</searchLink>; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Piekarz+R%22">Piekarz R</searchLink>; National Cancer Institute/Cancer Therapy Evaluation Program, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Hofmeister+CC%22">Hofmeister CC</searchLink>; Division of Hematology, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.<br /><searchLink fieldCode="AU" term="%22Welling+DB%22">Welling DB</searchLink>; Department of Otolaryngology Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Mortazavi+A%22">Mortazavi A</searchLink>; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University and The Comprehensive Cancer Center, Columbus, OH, USA. Amir.Mortazavi@osumc.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227806519%22">Cancer chemotherapy and pharmacology</searchLink> [Cancer Chemother Pharmacol] 2021 May; Vol. 87 (5), pp. 599-611. <i>Date of Electronic Publication: </i>2021 Jan 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>7806519 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0843 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203445704%22">03445704 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Chemother Pharmacol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33492438
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00280-020-04229-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 599
    Titles:
      – TitleFull: A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Collier KA
      – PersonEntity:
          Name:
            NameFull: Valencia H
      – PersonEntity:
          Name:
            NameFull: Newton H
      – PersonEntity:
          Name:
            NameFull: Hade EM
      – PersonEntity:
          Name:
            NameFull: Sborov DW
      – PersonEntity:
          Name:
            NameFull: Cavaliere R
      – PersonEntity:
          Name:
            NameFull: Poi M
      – PersonEntity:
          Name:
            NameFull: Phelps MA
      – PersonEntity:
          Name:
            NameFull: Liva SG
      – PersonEntity:
          Name:
            NameFull: Coss CC
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Khountham S
      – PersonEntity:
          Name:
            NameFull: Monk P
      – PersonEntity:
          Name:
            NameFull: Shapiro CL
      – PersonEntity:
          Name:
            NameFull: Piekarz R
      – PersonEntity:
          Name:
            NameFull: Hofmeister CC
      – PersonEntity:
          Name:
            NameFull: Welling DB
      – PersonEntity:
          Name:
            NameFull: Mortazavi A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2021 May
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0843
          Numbering:
            – Type: volume
              Value: 87
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Cancer chemotherapy and pharmacology
              Type: main
ResultId 1